Tablet is better all round for cancer patientsOctober 09, 2007A drug to treat colon cancer is proving much more convenient than traditional chemotherapy, has fewer side effects - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease. "Standard chemotherapy can be incredibly disruptive to people's lives," said Prof Professor Chris Twelves of the University of Leeds, who led the research. "Patients visit hospital five days a week for the injections and then have three weeks off before returning to hospital for the next course - and the side effects can be unpleasant." The oral chemotherapy drug Xeloda (capecitabine) offers fewer side-effects and less time in hospital - and the trial has shown that patients given the drug were at least as likely to be alive and free of their disease as those on standard chemotherapy (the Mayo Clinic regimen).
The research showed that about 71 percent of patients given Xeloda were still alive after five years, compared to 68 percent of patients treated with standard chemotherapy injections. Prof Twelves's study followed 1,987 patients who had undergone colon cancer surgery. It found that patients treated with Xeloda spent 85 percent less time with their doctor or at the hospital, and experienced fewer side effects. The new results, showing patients' five-year survival rates, confirm the effectiveness of the treatment. "We now have long-term evidence now that clearly supports Xeloda's superiority over the Mayo Clinic regimen," said Prof Twelves. "There is now no reason why we should ask colon cancer patients to endure the burdens associated with that older treatment." University of Leeds | |||||||||||||||||||||
|
Related Chemotherapy Current Events and Chemotherapy News Articles Iressa proves just as effective as chemotherapy for lung cancer Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center. Survival of head and neck cancer patients is greatly affected by coexisting ailments Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital. Study identifies causes of bone loss in breast cancer survivors Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss. Novel 4-drug combination proves safe for lung cancer treatment The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center. Researchers aim to over-stress already taxed mantle cell lymphoma cells Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them. Battling bacteria in the blood: Researchers tackle deadly infections It's a leading cause of death, but no one knows for sure how and why it happens. It's a major source of health care costs, adding days or weeks to the hospital stays and lost work time of millions of people. But no one fully understands how best to fight it. Cancer drugs my build and not tear down blood vessels Scientists have thought that one way to foil a tumor from generating blood vessels to feed its growth - a process called angiogenesis - was by creating drugs aimed at stopping a key vessel growth-promoting protein. But now the opposite seems to be true. Mayo Clinic Researchers Find Predictive Tests and Early Treatment Delay Progression of Blood Cell Cancer Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer. UC Davis researchers discover Achilles' heel in pancreatic cancer UC Davis Cancer Center researchers have discovered a metabolic deficiency in pancreatic cancer cells that can be used to slow the progress of the deadliest of all cancers. ESF workshop makes major advance in cancer radiotherapy Radical improvements in outcome for many cancer sufferers are in prospect following one of the most significant advances in radiotherapy since x-rays were first used to treat a tumour in 1904. More Chemotherapy Current Events and Chemotherapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||